Zai Lab Third Quarter 2026 Financial Results - ZAI LAB LTD

Financial Performance:

• Total revenue for the third quarter of 2026 reached $108.2 million, driven by a 2% sequential increase in net product revenue.
• The China commercial business remained profitable, demonstrating operational stability despite volume-based pricing dynamics.
• Operating expenses for R&D and SG&A remained relatively stable year-over-year, reflecting disciplined cost management and resource optimization.
• Cash position stood at $659.7 million as of September 30, 2026.
• A $250 million equity financing was raised in October at no discount to market, bolstering financial flexibility for global development.
• Adjusted loss from operations is referenced as a non-GAAP measure, with full details available in the SEC filing dated November 5, 2026.

Guidance and Future Outlook:

• Management expects a return to year-over-year product revenue growth in the China commercial business by 2027.
• Three registrational studies are targeted to be underway by year-end 2026 across small cell lung cancer (SCLC) and neuroendocrine carcinomas (NEC).
• Two registrational readouts and a potential US BLA submission are anticipated in 2027, with a potential US launch as early as 2028.
• Key commercial growth drivers for 2027 include new National Reimbursement Drug List (NRDL) inclusion for new products, volume expansion from key brands, and relief of supply constraints on core products like Xegduro.
• The company aims to present first-in-human data for the bispecific ZL1503 next week, with Phase IIb development planned for atopic dermatitis subsequently.

Business Segments and Product Lines:

• Oncology (Lead Program ZOSI): Data from a Phase I study in first-line SCLC showed an 81.8% confirmed objective response rate (ORR) and 81.9% 6-month progression-free survival (PFS) when combined with atezolizumab; Grade 3+ adverse events occurred in only 9.1% of patients.
• Oncology (Extrapulmonary NEC): Enrollment completed for a Phase 1b/2 study; preliminary results show ~40% response rates and 5-6 months durability, supporting a potential accelerated approval pathway via single-arm study with a confirmatory front-line trial starting early 2027.
• Immunology (ZL1503): An internally developed IL-13/IL-31 bispecific antibody for atopic dermatitis; first-in-human data will be presented next week, with plans for Phase IIb in the near term.
• Pipeline Expansion: Three additional oncology and immunology assets (ZL6201, CL1311, CL1222) are expected to advance in 2027.
• China Commercial: Priority brands Zedula and CoxT maintained competitive positions; Zedula saw sequential volume growth in new patient starts, and CoxT is gaining traction ahead of potential NRDL listing.
• Allergan/Other: Ongoing registration of AllegraBARC in thyroid eye disease and potential additional filings for efacizumab.

Market and Competitive Landscape:

• ZOSI is positioned to challenge the standard of care (chemo-immunotherapy) in first-line SCLC, offering superior tolerability (9.1% Grade 3+ vs. ~60% Grade 2+ for chemo-IO) and comparable or better efficacy.
• Collaborations with Amgen (T-cell engager tarlatamab) and BioAtla (BIA) aim to create a "backbone" strategy for SCLC, potentially combining ZOSI with T-cell engagers to maximize tumor burden reduction and immune durability.
• The SCLC market is evolving with the introduction of Tarlatamab; management anticipates ZOSI could become a preferred regimen over traditional 40-year-old chemo protocols if safety and efficacy data hold.
• The atopic dermatitis market faces competition from existing biologics; ZL1503 differentiates via dual-pathway blockade (itch and inflammation) and YTE modification for extended half-life/less frequent dosing.

Risks and Challenges:

• Clinical Success: Regulatory approval is contingent on positive interim analysis results (200 patients) for the Phase III trial and confirmatory studies for accelerated approval pathways.
• Competitive Pressure: The emergence of Tarlatamab as a frontline therapy could alter treatment paradigms, requiring ZOSI to demonstrate superior or complementary value in head-to-head or combination settings.
• Regulatory Uncertainty: The path to accelerated approval relies on specific response rate thresholds and follow-up durability data, which may face scrutiny.
• Market Dynamics: Continued volume-based pricing in China and competitive pressure in the PARP inhibitor landscape for existing products.
• Execution: Delays in patient enrollment for global Phase III studies or clinical trial readouts could impact the 2027 timeline.

Management Commentary and Tone:

• Management displayed high confidence, describing the current period as "pivotal" and the potential ZOSI launch as a "defining achievement."
• Tone was optimistic yet disciplined, emphasizing the strength of the profitable China business as a foundation for funding the global pipeline.
• Dr. Du highlighted that the vision is "within reach" with ZOSI advancing toward a BLA, while Dr. Amado emphasized the unprecedented nature of the ZOSI data in an unselected SCLC population.
• Management reaffirmed the commitment to executing the global program internally while remaining open to partnerships if they accelerate patient access or increase shareholder value.

Analyst Questions and Answers:

• Accelerated Approval Criteria (JPMorgan): Management confirmed an interim analysis with 200 patients (post-platinum/carlatamab progression) is designed to assess durability (6-month follow-up) for potential accelerated approval based on response rate; the study is overpowered relative to historical 20% response rates.
• Amgen Collaboration & Launch Strategy (UBS): The ZOSI-Amgen (Tarlatamab) collaboration is progressing well with two dose levels tested for combinability; management plans to launch ZOSI internally but is open to global partner evaluations. The combination is viewed as superior to Tarlatamab monotherapy for maintaining disease control.
• NEC Strategy & TCE Regimen (Cantor Fitzgerald): FDA alignment supports a single-arm accelerated approval for NEC with a confirmatory front-line study starting early 2027; management expects the ZOSI+TCE combination with Amgen to move faster than with BioAtla, pending data.
• China Revenue Drivers (Citigroup): Stronger-than-expected New Zyl (New Zedula) sales were attributed to strong partner execution and market traction; the trend is expected to continue.
• Frontline Strategy vs. Tarlatamab (Living Partners): If Tarlatamab proves successful in induction, the industry may shift away from traditional chemo; ZOSI is being positioned as a safer, potentially more effective alternative or combination partner to avoid chemo toxicity.
• 2027 Growth Drivers (GomezX): Confident in 2027 growth driven by NRDL expansion, volume from core brands (Zedula, CoxT), and relief of supply constraints for Xegduro.

Other Key Points:

• The company is advancing a "backbone" strategy where ZOSI rapidly reduces tumor burden, complemented by T-cell engagers for durable immune-mediated treatment.
• Management noted that the 1.6 mg/kg dose of ZOSI demonstrated a safety profile with only one case of Grade 1 interstitial lung disease in the monotherapy experience.
• The earnings call included forward-looking statements subject to risks regarding regulatory approvals, clinical trial outcomes, and market acceptance.
• Future data presentations are scheduled for the North American Neuroendocrine Tumor Society Conference and the American College of Allergy, Asthma, and Immunology meeting.